

## HR 5982

### Safe Medicine Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 26, 2020

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (Feb 26, 2020)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/5982>

### Sponsor

**Name:** Rep. Posey, Bill [R-FL-8]

**Party:** Republican • **State:** FL • **Chamber:** House

### Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Ryan, Tim [D-OH-13]	D · OH		Feb 26, 2020
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Mar 2, 2020
Rep. Meadows, Mark [R-NC-11]	R · NC		Mar 2, 2020

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 26, 2020

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
116 HR 5927	Related bill	<b>Feb 18, 2020:</b> Referred to the House Committee on Energy and Commerce.

### Summary (as of Feb 26, 2020)

#### Safe Medicine Act

This bill authorizes the Food and Drug Administration to temporarily ban the sale of a drug if (1) the drug (or an active ingredient of the drug) is manufactured in a country that, because of systemic problems of supervision, may be producing contaminated drugs; and (2) the drug's labeling does not have certain warnings about potential contamination.

The bill also requires the Department of Health and Human Services to report to Congress on vulnerabilities in the U.S. medicine supply chain, including vulnerabilities related to reliance on production from other countries.

## Actions Timeline

---

- **Feb 26, 2020:** Introduced in House
- **Feb 26, 2020:** Referred to the House Committee on Energy and Commerce.